Key features and details
- Sensitivity: 0.26 ng/ml
- Range: 0.625 ng/ml - 40 ng/ml
- Sample type: Cell culture supernatant, Plasma, Serum, Tissue, Urine
- Detection method: Colorimetric
- Assay type: Sandwich (quantitative)
- Reacts with: Human
Product nameHuman Plasminogen ELISA Kit (PLG)
See all Plasminogen kits
Intra-assay Sample n Mean SD CV% Overall 5.1% Inter-assay Sample n Mean SD CV% Overall 9.7%
Sample typeCell culture supernatant, Urine, Serum, Plasma, Tissue
Assay typeSandwich (quantitative)
Sensitivity= 0.26 ng/ml
Range0.625 ng/ml - 40 ng/ml
= 101 %
Assay time3h 00m
Assay durationMultiple steps standard assay
Species reactivityReacts with: Human
Human Plasminogen ELISA kit (PLG) is designed for the quantitative measurement of Plasminogen (PLG) concentrations in Human plasma, serum, urine, saliva, milk, tissue samples, cerebrospinal fluid and cell culture supernatants.
A Plasminogen specific antibody has been precoated onto 96-well plates and blocked. Standards or test samples are added to the wells and subsequently a Plasminogen specific biotinylated detection antibody is added and then followed by washing with wash buffer. Streptavidin-Peroxidase Conjugate is added and unbound conjugates are washed away with wash buffer. TMB is then used to visualize Streptavidin-Peroxidase enzymatic reaction. TMB is catalyzed by Streptavidin-Peroxidase to produce a blue color product that changes into yellow after adding acidic stop solution. The density of yellow coloration is directly proportional to the amount of Plasminogen captured in plate.
Get higher sensitivity in only 90 minutes with Human Plasminogen ELISA Kit (ab196262) from our SimpleStep ELISA® range.
The entire kit may be stored at -20°C for long term storage before reconstitution - Avoid repeated freeze-thaw cycles.
Storage instructionsStore at -20°C. Please refer to protocols.
Components 1 x 96 tests 100X Streptavidin-Peroxidase Conjugate 1 x 80µl 10X Diluent M Concentrate 1 x 30ml 20X Wash Buffer Concentrate 2 x 30ml 50X Biotinylated Human Plasminogen Antibody 1 x 120µl Chromogen Substrate 1 x 7ml Plasminogen Microplate (12 x 8 well strips) 1 unit Plasminogen Standard 1 vial Sealing Tapes 3 units Stop Solution 1 x 11ml
FunctionPlasmin dissolves the fibrin of blood clots and acts as a proteolytic factor in a variety of other processes including embryonic development, tissue remodeling, tumor invasion, and inflammation. In ovulation, weakens the walls of the Graafian follicle. It activates the urokinase-type plasminogen activator, collagenases and several complement zymogens, such as C1 and C5. Cleavage of fibronectin and laminin leads to cell detachment and apoptosis. Also cleaves fibrin, thrombospondin and von Willebrand factor. Its role in tissue remodeling and tumor invasion may be modulated by CSPG4. Binds to cells.
Angiostatin is an angiogenesis inhibitor that blocks neovascularization and growth of experimental primary and metastatic tumors in vivo.
Tissue specificityPresent in plasma and many other extracellular fluids. It is synthesized in the liver.
Involvement in diseaseDefects in PLG are a cause of susceptibility to thrombosis (THR) [MIM:188050]. It is a multifactorial disorder of hemostasis characterized by abnormal platelet aggregation in response to various agents and recurrent thrombi formation.
Defects in PLG are the cause of plasminogen deficiency (PLGD) [MIM:217090]. PLGD is characterized by decreased serum plasminogen activity. Two forms of the disorder are distinguished: type 1 deficiency is additionally characterized by decreased plasminogen antigen levels and clinical symptoms, whereas type 2 deficiency, also known as dysplasminogenemia, is characterized by normal, or slightly reduced antigen levels, and absence of clinical manifestations. Plasminogen deficiency type 1 results in markedly impaired extracellular fibrinolysis and chronic mucosal pseudomembranous lesions due to subepithelial fibrin deposition and inflammation. The most common clinical manifestation of type 1 deficiency is ligneous conjunctivitis in which pseudomembranes formation on the palpebral surfaces of the eye progresses to white, yellow-white, or red thick masses with a wood-like consistency that replace the normal mucosa.
Sequence similaritiesBelongs to the peptidase S1 family. Plasminogen subfamily.
Contains 5 kringle domains.
Contains 1 PAN domain.
Contains 1 peptidase S1 domain.
DomainKringle domains mediate interaction with CSPG4.
modificationsN-linked glycan contains N-acetyllactosamine and sialic acid. O-linked glycans consist of Gal-GalNAc disaccharide modified with up to 2 sialic acid residues (microheterogeneity).
In the presence of the inhibitor, the activation involves only cleavage after Arg-580, yielding two chains held together by two disulfide bonds. In the absence of the inhibitor, the activation involves additionally the removal of the activation peptide.
Cellular localizationSecreted. Locates to the cell surface where it is proteolytically cleaved to produce the active plasmin. Interaction with HRG tethers it to the cell surface.
- Information by UniProt
- Plasmin heavy chain A
- Plasmin light chain B
ab108893 has been referenced in 2 publications.
- Zitur LJ et al. Brain Death Enhances Activation of the Innate Immune System and Leads to Reduced Renal Metabolic Gene Expression. Transplantation 103:1821-1833 (2019). PubMed: 30964836
- Banville N et al. A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM). PLoS One 9:e105365 (2014). Sandwich ELISA ; Human . PubMed: 25133674